Literature DB >> 9259428

Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs.

S F Lanes1, L L Lanza, P W Radensky, R A Yood, R F Meenan, A M Walker, N A Dreyer.   

Abstract

OBJECTIVE: To describe the frequency and costs of medical services for patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a managed care setting.
METHODS: Individual utilization records of medical and pharmacy services for OA and RA patients were obtained from a group-model health maintenance organization (HMO). Estimates were made for costs of drugs and medical services for arthritis from July 1, 1993 to June 30, 1994 using Medicare reimbursement schedules and average wholesale drug prices. Calculated rates for each population were expressed as counts of events or as dollars per person-year.
RESULTS: The average individual cost rate of arthritis-related care for 365 RA patients was $2,162 per year, and the total cost of RA care to the HMO was $703,053. Prescription medications accounted for 62% ($436,440) of the total cost of RA care, while ambulatory care accounted for 21% ($150,938), and hospital visits accounted for 16% ($115,674). With regard to 10,101 OA patients, the average individual cost rate was $543 per year, and total cost to the HMO was $4,728,425. Hospital care accounted for 46% ($2,170,890) of the total cost of OA care, medications accounted for 32% ($1,509,637), and ambulatory care accounted for 22% ($1,047,898).
CONCLUSION: RA care, in the setting of this study, was characterized by intensive treatment, especially frequent use of medications that were delivered to most patients. Although the cost of RA care per patient was high, cost to the managed care provider was relatively low, owing to the rarity of RA. OA care tended to be infrequent, and the largest component of cost was hospital care for a small proportion of patients (5%). Owing to the greater prevalence of OA, care of OA was nearly 7 times more costly to the managed care provider than was care of RA.

Entities:  

Mesh:

Year:  1997        PMID: 9259428     DOI: 10.1002/art.1780400816

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

1.  Degenerative musculoskeletal disease.

Authors:  O Ethgen; J-Y Reginster
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

2.  Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS.

Authors:  Steven Simoens; Sandra De Coster; Bernard De Ruyck; Petra Stutz; Gert Laekeman
Journal:  Pharm World Sci       Date:  2006-11-17

Review 3.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  [Direct costs of osteoarthritis].

Authors:  Ernst Wagner
Journal:  Wien Med Wochenschr       Date:  2011-01

6.  Cognitive-behavioral therapy for insomnia in knee osteoarthritis: a randomized, double-blind, active placebo-controlled clinical trial.

Authors:  Michael T Smith; Patrick H Finan; Luis F Buenaver; Mercedes Robinson; Uzma Haque; Angela Quain; Erin McInrue; Dingfen Han; Jeannie Leoutsakis; Jennifer A Haythornthwaite
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

7.  Associations Between Patient Characteristics and the Amount of Arthritis Medication Information Patients Receive.

Authors:  Lorie Love Geryk; Susan Blalock; Robert F DeVellis; Kristen Morella; Delesha Miller Carpenter
Journal:  J Health Commun       Date:  2016-09-26

8.  Ambulatory visit utilization in a national, population-based sample of adults with osteoarthritis.

Authors:  Miriam G Cisternas; Edward Yelin; Jeffrey N Katz; Daniel H Solomon; Elizabeth A Wright; Elena Losina
Journal:  Arthritis Rheum       Date:  2009-12-15

9.  Determinants of direct costs in Dutch rheumatoid arthritis patients.

Authors:  S M M Verstappen; H Verkleij; J W J Bijlsma; E Buskens; A A Kruize; A H M Heurkens; M J Van Der Veen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

10.  Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain.

Authors:  M V Hurley; N E Walsh; H L Mitchell; T J Pimm; E Williamson; R H Jones; B C Reeves; P A Dieppe; A Patel
Journal:  Arthritis Rheum       Date:  2007-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.